4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 112 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $35,365,302 | -29.6% | 2,778,107 | 0.0% | 1.36% | -41.3% |
| Q2 2023 | $50,200,393 | +28.2% | 2,778,107 | +21.9% | 2.32% | +44.5% |
| Q1 2023 | $39,160,659 | -33.6% | 2,278,107 | -14.3% | 1.61% | -35.1% |
| Q4 2022 | $59,009,771 | +129.6% | 2,656,901 | -16.9% | 2.48% | +110.5% |
| Q3 2022 | $25,701,000 | +17.3% | 3,196,642 | +1.8% | 1.18% | -18.3% |
| Q2 2022 | $21,917,000 | -40.8% | 3,140,000 | +28.3% | 1.44% | -39.3% |
| Q1 2022 | $37,017,000 | -11.2% | 2,448,200 | +28.9% | 2.37% | -19.3% |
| Q4 2021 | $41,686,000 | – | 1,900,000 | – | 2.94% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,007,413 | $68,887,429 | 2.52% |
| Opaleye Management Inc. | 314,000 | $5,397,660 | 1.62% |
| Deep Track Capital, LP | 2,278,107 | $39,160,659 | 1.61% |
| Casdin Capital, LLC | 1,070,000 | $18,393,300 | 1.52% |
| Eagle Health Investments LP | 437,911 | $7,527,690 | 1.46% |
| ACUTA CAPITAL PARTNERS, LLC | 104,753 | $1,800,704 | 1.33% |
| Octagon Capital Advisors LP | 499,996 | $8,594,931 | 1.24% |
| Soleus Capital Management, L.P. | 469,400 | $8,068,986 | 0.84% |
| Novo Holdings A/S | 700,000 | $12,033,000 | 0.79% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $67,692,742 | 0.32% |